Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Nkarta, Inc.

NASDAQ: NKTX · Life Sciences · 4 alerts · CIK 1787400

Share price
$1.21Close, Nov 16
Market cap
$86.8M
Shares outstanding
71.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nkarta, Inc. filings on SEC EDGAR ↗

9:21 AM ET 8-K
Clinical Trial Data

Nkarta Clinical Trial Data

Nkarta announced positive initial clinical data from its Ntrust program evaluating NKX019, an allogeneic CAR NK cell therapy, for myositis and systemic sclerosis. In the 4 billion cells per dose cohort, 83% of myositis patients achieved moderate or major responses, while 86% of systemic sclerosis patients achieved an rCRISS-25 response or greater. The therapy demonstrated a favorable safety profile with no cases of CRS, ICANS, or GvHD across 40 treated patients.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.